Skip to content
MARKETS / NASDAQ / SHC
NASDAQ · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC · LARGE CAP

Sotera Health Co. SHC

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.2B
▲ 5.7% YoY
$77.9M
▲ 75.6% YoY
$149.2M
▲ 230.8% YoY
In brief

What this company does

Sotera Health Company provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services for medical, pharmaceutical and food products in the United States and around the world. As of December 31, 2025, it employed over 3,000 employees worldwide. In 2025, its customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies, based on revenue. Its sterilization services business comprises Sterigenics and Nordion. Its lab testing and advisory services business consists of Nelson Labs, which provides outsourced microbiological and analytical chemistry testing services for the medical device and pharmaceutical industries. Its Sterigenics business offers customers terminal sterilization services, primarily using three major commercial sterilization technologies: gamma irradiation, EO processing and E-beam irradiation. Its Nordion business supplies Co-60, used in sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer.

Written from the business description in Sotera Health Co's annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth
USD 1.2B
Revenue, FY2025 · full 7-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.2 · Net income 0.1
0.40B0.80B-0.08B-0.16B2019202020212022202320242025
Compound annual growth
+5.1%
+7.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +7.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
7 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 12.7% · Net 6.7%
10%20%-10%-20%2019202020212022202320242025
ROE
FY2025 · ROE 15.4%
10%20%-20%-40%2019202020212022202320242025

Each USD of equity produced 15 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 149.2
80M160M-200M2019202020212022202320242025
Net buybacks $B Dividends $B
FY2022 · Dividends — · Net buybacks 0.0
0.25B0.50B-0.40B-0.80B2019202020212022

Total assetsUSD 3.3B
EquityUSD 606.0M
CashUSD 344.6M
Gross debtUSD 2.1B
Net debtUSD 1.8B
Current ratio2.46×

Net debt stands at 296% of equity.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B1.21.11.01.00.90.80.8
Operating income $B0.10.10.10.20.30.20.2
EBITDA $B0.20.20.20.30.30.30.3
Income tax $B0.10.10.1−0.00.1−0.00.0
Net income $B0.10.00.1−0.20.1−0.0−0.0
Free cash flow $B0.10.0−0.40.10.20.10.1
EPS, diluted $0.270.160.18−0.830.41−0.16−0.09
Dividend / sh $·······
Payout %····0−0−3315
ROE %15.410.512.9−49.922.5−8.5·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Misc Health & Allied Services, NEC
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image